SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60  millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 17571.60 14327.50 22.64 17571.60 14327.50 22.64 60890.70 52169.80 16.72
Other Income 200.70 215.20 -6.74 200.70 215.20 -6.74 774.30 1004.70 -22.93
PBIDT 5191.30 3489.00 48.79 5191.30 3489.00 48.79 15156.90 10448.00 45.07
Interest 352.00 438.90 -19.80 352.00 438.90 -19.80 1429.60 1822.00 -21.54
PBDT 4839.30 3050.10 58.66 4839.30 3050.10 58.66 13727.30 8626.00 59.14
Depreciation 957.60 935.70 2.34 957.60 935.70 2.34 3786.40 3587.90 5.53
PBT 3881.70 2114.40 83.58 3881.70 2114.40 83.58 9940.90 5038.10 97.31
TAX 982.10 535.00 83.57 982.10 535.00 83.57 2536.10 1234.20 105.49
Deferred Tax -50.40 -61.60 -18.18 -50.40 -61.60 -18.18 -315.10 -304.20 3.58
PAT 2899.60 1579.40 83.59 2899.60 1579.40 83.59 7404.80 3803.90 94.66
Equity 1080.50 1079.60 0.08 1080.50 1079.60 0.08 1079.70 1078.50 0.11
PBIDTM(%) 29.54 24.35 21.32 29.54 24.35 21.32 24.89 20.03 24.29

Laurus Labs Share Price

1602.30 34.00 (2.17%)
24-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1941.00
Dr. Reddys Labs. 1152.60
Cipla 1410.90
Lupin 2369.45
Zydus Lifesciences 1108.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: